India's Zydus Lifesciences falls after US FDA inspection ends with five observations
BUZZ-India's Zydus Lifesciences falls after US FDA inspection ends with five observations ** Shares of pharmaceuticals company Zydus LifesciencesZYDU.NS fell as much as 2.03% to 1,109.50 rupees
** US FDA closed inspection at co's Ahmedabad manufacturing plant with five observations, co said
** ZYDU closely working with FDA to address observations--statement
** Stock's F12M PE ratio of 24.98 vs industry median of 25.98--LSEG-compiled data
** 29 analysts, on average, rate the stock "hold", median TP at 1,205 rupees--LSEG-compiled data
** YTD, shares up 21.65%
(Reporting by Saikeerthi in Bengaluru)
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka